Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China

Wei, Qiran; Xu, YuTing; Liu, Wei; Guan, Xin

doi:10.1186/s12962-023-00499-9

Cost Effectiveness and Resource Allocation

Table 2 Base case and scenario analysis results

From: Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China

Model	Results	ABE + ET	ET	Difference
Base-case analysis	LYs
	LYs in iDFS	12.90	11.84	1.06
	LYs in nonmetastatic recurrence	0.27	0.39	− 0.12
	LYs in remission	0.25	0.36	− 0.11
	LYs in distant metastases	0.39	0.56	− 0.18
	Total LYs	13.80	13.15	0.65
	QALYs
	QALYs in iDFS	12.44	11.43	1.02
	QALYs in nonmetastatic recurrence	0.20	0.30	− 0.09
	QALYs in remission	0.21	0.31	− 0.10
	QALYs in distant metastases	0.25	0.36	− 0.11
	Total QALYs	13.11	12.39	0.72
	Costs ($)
	Costs in iDFS	24,213.41	5964.31	18,249.10
	Costs in nonmetastatic recurrence	1,927.17	2800.09	− 872.92
	Costs in remission	24.04	34.53	− 10.48
	Costs in distant metastases	2,573.46	3739.96	− 1166.50
	Costs in end-of-life care	311.19	452.68	− 141.49
	Total Costs	29,049.28	12,991.56	16,057.72
	ICER ($/LY)	24,841
	ICER ($/QALY)	22,385
Scenario 1 (simulated until the expected life expectancy)	LYs
	LYs in iDFS	11.65	10.72	0.93
	LYs in nonmetastatic recurrence	0.27	0.39	− 0.12
	LYs in remission	0.24	0.35	− 0.11
	LYs in distant metastases	0.38	0.55	− 0.17
	Total LYs	12.54	12.01	0.52
	QALYs
	QALYs in iDFS	11.24	10.35	0.89
	QALYs in nonmetastatic recurrence	0.20	0.30	− 0.09
	QALYs in remission	0.21	0.30	− 0.09
	QALYs in distant metastases	0.24	0.35	− 0.11
	Total QALYs	11.89	11.30	0.60
	Costs ($)
	Costs in iDFS	24,213.41	5964.31	18,249.10
	Costs in nonmetastatic recurrence	1927.17	2799.89	− 872.72
	Costs in remission	24.04	34.53	− 10.48
	Costs in distant metastases	2532.04	3677.10	− 1145.07
	Costs in end-of-life care	305.81	444.51	− 138.70
	Total Costs	29,002.47	12,920.34	16,082.13
	ICER ($/LY)	30,741
	ICER ($/QALY)	26,945
Scenario 2 (mixture cure model)	LYs
	LYs in iDFS	13.47	11.99	1.48
	LYs in nonmetastatic recurrence	0.20	0.37	− 0.17
	LYs in remission	0.19	0.35	− 0.16
	LYs in distant metastases	0.29	0.54	− 0.25
	Total LYs	14.14	13.24	0.90
	QALYs
	QALYs in iDFS	12.99	11.57	1.43
	QALYs in nonmetastatic recurrence	0.15	0.29	− 0.13
	QALYs in remission	0.16	0.29	− 0.13
	QALYs in distant metastases	0.19	0.34	− 0.16
	Total QALYs	13.49	12.49	1.00
	Costs ($)
	Costs in iDFS	24,346.98	6005.42	18,341.56
	Costs in nonmetastatic recurrence	1462.81	2678.69	− 1215.89
	Costs in remission	20.69	32.74	− 12.05
	Costs in distant metastases	1951.64	3578.09	− 1626.45
	Costs in end-of-life care	234.06	433.32	− 199.26
	Total Costs	28,016.18	12,728.27	15,287.91
	ICER ($/LY)	16,959
	ICER ($/QALY)	15,264
Scenario 3 (non-mixture cure mode)	LYs
	LYs in iDFS	13.44	11.66	1.78
	LYs in nonmetastatic recurrence	0.20	0.41	− 0.21
	LYs in remission	0.19	0.38	− 0.19
	LYs in distant metastases	0.29	0.59	− 0.30
	Total LYs	14.13	13.05	1.08
	QALYs
	QALYs in iDFS	12.97	11.25	1.72
	QALYs in nonmetastatic recurrence	0.16	0.31	− 0.16
	QALYs in remission	0.16	0.32	− 0.16
	QALYs in distant metastases	0.19	0.38	− 0.19
	Total QALYs	13.48	12.27	1.20
	Costs ($)
	Costs in iDFS	24,322.64	5968.54	18,354.10
	Costs in nonmetastatic recurrence	1484.96	2948.07	− 1463.11
	Costs in remission	21.15	33.86	− 12.71
	Costs in distant metastases	1981.09	3939.30	− 1958.21
	Costs in end-of-life care	237.48	478.88	− 241.40
	Total Costs	28,047.32	13,368.65	14,678.67
	ICER ($/LY)	13,560
	ICER ($/QALY)	12,191

ABE + ET: abemaciclib + endocrine therapy; ET: endocrine therapy; LY: life-year; ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life-year

Back to article page

ISSN: 1478-7547

Contact us

General enquiries: journalsubmissions@springernature.com